"""!
` 
`
`
`
` 

    #
`
` !
`   ! 
`   

`
`
`AFFIDAVIT OF DUNCAN HALL
`
` 
`
` (4 ( ,*69+: ,8<,:; 96*,::69 (; ;/, 5;,95,; 9*/0=, 36*(;,+ 05 (5 9(5*0:*6
`(30-6950(  4(2, ;/0: +,*3(9(;065 6- 4@ 6>5 7,9:65(3 256>3,+.,
`
`
` /, 5;,95,; 9*/0=, 0: ( >,):0;, ;/(; 796=0+,: (**,:: ;6 ( +0.0;(3 30)9(9@ 6- 5;,95,;
`:0;,: (5+ 6;/,9 *<3;<9(3 (9;0-(*;: 05 +0.0;(3 -694 02, ( 7(7,9 30)9(9@ >, 796=0+,
`-9,, (**,:: ;6 9,:,(9*/,9: /0:;690(5: :*/63(9: (5+ ;/, .,5,9(3 7<)30* /, 5;,95,;
`9*/0=, /(: 7(9;5,9,+ >0;/ (5+ 9,*,0=,: :<7769; -964 =(906<: 05:;0;<;065:
`05*3<+05. ;/, 0)9(9@ 6- 65.9,::
`
` /, 5;,95,; 9*/0=, /(: *9,(;,+ ( :,9=0*, 256>5 (: ;/, #(@)(*2 (*/05, /,
`#(@)(*2 (*/05, 4(2,: 0; 76::0)3, ;6 )96>:, 469, ;/(5

 )033065 7(.,: :;69,+
`05 ;/, 5;,95,; 9*/0=,: >,) (9*/0=, "0:0;69: ;6 ;/, #(@)(*2 (*/05, *(5 :,(9*/
`(9*/0=,: )@ ! 0, ( >,):0;, (++9,:: - (9*/0=,+ 9,*69+: -69 ( ! (9,
`(=(03()3, ;/, =0:0;69 >033 ), 79,:,5;,+ >0;/ ( +0:73(@ 6- (=(03()3, +(;,: /, =0:0;69
`4(@ :,3,*; 65, 6- ;/6:, +(;,: (5+ ),.05 )96>:05. (5 (9*/0=,+ =,9:065 6- ;/, #,)
`052: 65 (9*/0=,+ -03,: 05 ;/, #(@)(*2 (*/05, 7605; ;6 6;/,9 (9*/0=,+ -03,:
` >/,;/,9   7(.,: 69 6;/,9 -03, ;@7,: 0- (5@ (9, -6<5+ -69 ;/, ! 05+0*(;,+
`)@ ( .0=,5 3052 69 05:;(5*, ;/, #(@)(*2 (*/05, 0: +,:0.5,+ :<*/ ;/(; >/,5 (
`=0:0;69 *30*2: 65 ( /@7,93052 65 (5 (9*/0=,+ 7(., ;/(; 7605;: ;6 (56;/,9 ! ;/,
`=0:0;69 >033 ), :,9=,+ ;/, (9*/0=,+ -03, -6<5+ -69 ;/, /@7,93052C: ! >0;/ ;/,
`*36:,:; (=(03()3, +(;, ;6 ;/, 050;0(3 -03, *65;(0505. ;/, /@7,93052
`
`

 /, (9*/0=,+ +(;( 4(+, =0,>()3, (5+ )96>:,()3, )@ ;/, #(@)(*2 (*/05, 0:
`6);(05,+ )@ <:, 6- >,) (9*/0=05. :6-;>(9, ;/(; (<;64(;0*(33@ :;69,: *670,: 6- -03,:
`(=(03()3, =0( ;/, 5;,95,; ,(*/ -03, 79,:,9=,+ (: 0; ,?0:;,+ (; ( 7(9;0*<3(9 7605; 05
`;04,
`
`  /, 5;,95,; 9*/0=, (::0.5: ( ! 65 0;: :0;, ;6 ;/, (9*/0=,+ -03,: 05 ;/, -694(;
`/;;7>,)(9*/0=,69.>,)%$,(9 05 @@@@&%65;/ 05 44&%(@ 05 ++&% 04, *6+, 05
`//44::&%9*/0=,+ !& (2( (5 A,?;,5+,+ !B /<: ;/, ,?;,5+,+ !
`/;;7>,)(9*/0=,69.>,) 
`


`/;;7>>>(9*/0=,69. >6<3+ ), ;/,
`! -69 ;/, 9,*69+ 6- ;/, 5;,95,; 9*/0=, /64, 7(.,   -03,
` /;;7>>>(9*/0=,69. (9*/0=,+ 65 (5<(9@
`  (;

  (4 (5+
`
`:,*65+:  
` (; 

 
`  >,) )96>:,9 4(@ ), :,; :<*/ ;/(; ( 7905;6<;
`-964 0; >033 +0:73(@ ;/, ! 6- ( >,) 7(., 05 ;/, 7905;6<;C: -66;,9 /, +(;,
`05+0*(;,+ )@ (5 ,?;,5+,+ ! (7730,: ;6 ( 79,:,9=,+ 05:;(5*, 6- ( -03, -69 ( .0=,5
`! )<; 56; 5,*,::(903@ ;6 (5@ 6;/,9 -03,: 3052,+ ;/,9,05 /<: 05 ;/, *(:, 6- (
`7(., *65:;0;<;,+ )@ ( 7904(9@   -03, (5+ 6;/,9 :,7(9(;, -03,: ,. -03,: >0;/
`04(.,: (<+06 4<3;04,+0( +,:0.5 ,3,4,5;: 69 6;/,9 ,4),++,+ *65;,5; 3052,+
`>0;/05 ;/(; 7904(9@   -03, ;/, 7904(9@   -03, (5+ ;/, 6;/,9 -03,: >033 ,(*/
`/(=, ;/,09 6>5 9,:7,*;0=, ,?;,5+,+ !: (5+ 4(@ 56; /(=, ),,5 (9*/0=,+ 65 ;/,
`:(4, +(;,:
`
`Apotex Exhibit 1022
`Page 1 of 11
`
`

`

`ARCHIVE
`
`a[
`
`a4
`se
`
`me
`ea}
`
` ;;(*/,+ /,9,;6 (: ?/0)0;  (9, ;9<, (5+ (**<9(;, *670,: 6- 7905;6<;: 6-
`Attached hereto as Exhibit A are true and accurate copies of printouts of
`:*9,,5:/6;: 6- ;/, 5;,95,; 9*/0=,: 9,*69+: 6- ;/, (9*/0=,+ -03,: -69 ;/, !: (5+
`screenshots of the Internet Archive's records of the archived files for the URLs and
`;/, +(;,: :7,*0-0,+ 05 ;/, (;;(*/,+ *6=,9:/,,; 6- ,(*/ 7905;6<;
`the dates specified in the attached coversheet of each printout.
`
`
`
` +,*3(9, <5+,9 7,5(3;@ 6- 7,91<9@ ;/(; ;/, -69,.605. 0: ;9<, (5+ *699,*;
`I declare under penalty of perjury that the foregoing is true and correct.
`
`01/27/2021 eee? YUeaALL
`
`01/27/2021
`  ''''''''''''''''''''''''
`''''''''''''''''''''''''
`DATE:
`<5*(5 (33
`Duncan Hall
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 2 of 11
`Page 2 of 11
`
`=c
`
`e=
`
`

`

`EXHIBIT A
`EXHIBIT A
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 3 of 11
`Page 3 of 11
`
`

`

`
`
` #" # 
`

 



 
`  !
`https://web.archive.org/web/20090813064936/https://clinicaltrials.gov/ct2/show/NCT006373
`!!
`77
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 4 of 11
`Page 4 of 11
`
`

`

`
`
`Home StudyTopics Glossary Search
`
`
`
`
`
`| Search
`
`
`
`https: //clinicaltrials.gov/ct2 /show/NCT00637377
`INTERNET ARCHIVE
`
`
`
`
`Wayogebmactine21captures
`18 Jan 2009 - 23 Jan 2017
`tat
`ron odes
`0&
`2010 QaNrnauremetadics
`Skip to Main Content
`ClinicalTrials.gov
`Aservice of the U.S. National Institutes of Health
`
`
`( Tabular View | ( No Study Results Posted
`
`Full Text View
`
`Related Studies
`
`|
`
`Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)
`
`This study is currently recruiting participants.
`Verified by Bayer, July 2009
`
`
`First Received: March 12,2008 Last Updated: July 3, 2009 History of Changes
`
`ClinicalTrials.gov Identifier:|NCT00637377
`
`Information provided by:
`
`> Purpose
`
`This study is a phase III, double-masked, randomized,study ofthe efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
`Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
`
` Macular Degeneration
`
`Drug: VEGF Trap-Eye
`Drug: Ranibizumab
`
`PhaseIII
`
`Interventional
`Study Type:
`Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
`
`Official Title:|A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Dosesof Intravitreal VEGF Trap in Subjects
`With Neovascular Age-Related Macular Degencration (AMD).
`
`Resource links provided by NLM:
`
`Genetics Home Referencerelated topics: X-linked juvenile retinoschisis
`
`MedlinePlus related topics: Macular Degeneration
`
`Drug Information available for: Ranibizumab Aflibercept
`US. FDA Resources
`
`Further study details as provided by Bayer:
`
`Primary Outcome Measures:
`e The proportion of subjects who maintain vision at Week 52, where a subjectis classified as maintaining vision if the subject has lost fewer than 15 letters on the ETDRSchart
`comparedto baseline (ie, prevention of moderate vision loss) [ Time Frame: week 52 ] [ Designated as safety issue: Yes]
`
`Secondary Outcome Measures:
`¢ Mean change from baseline in BCVA as measured by ETDRSletter score at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: Yes ]
`e The proportion of subjects who gain at least 15 letters of vision at Week 52 [ Time Frame: week 52 ] [| Designated as safety issue: No ]
`¢ Mean change from baseline in total NEI VFQ-25 score at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: No ]
`¢ Mean change from baseline in CNV area at Week 52 [ Time Frame: week 52 ] [ Designated as safety issue: Yes ]
`
`Estimated Enrollment:
`Study Start Date:
`Estimated Study Completion Date:
`Estimated Primary Completion Date:
`
`1200
`April 2008
`September 2011
`July 2011 (Final data collection date for primary outcome measure)
`
`Experimental
`
`Drug: VEGFTrap-Eye
`2.0 mg VEGFTrap-Eye administered every 8 weeks(including one additional 2,0 mg dose at Week 4) during the first year. Thereafter a dose may be
`administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
`
`Assigned Interventions Arm 3:
`
`Arm 1:
`Experimental
`
`Arm 2:
`Experimental
`
`Drug: VEGFTrap-Eye
`0.5 mg VEGF Trap-Eye administered every 4 weeksduring the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no
`less frequently than every 12 weeks.
`
`Drug: VEGF Trap-Eye
`Vann Lan wee ne,41e- shen 22 enee AD ween nT
`2.0 mg VEGFTrap-Eye administered every 4 weeksduring thefirst year. Thereafter a dose may be administered as frequently as every 4 weeks, but no
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 5 of 11
`Page 5 of 11
`
`

`

`Jess LICYUCLILLY Widll CVELY 12 WCCKS.
`
`Arm 4: Active
`Comparator
`
`every 12 weeks.
`
`Drug: Ranibizumab
`0.5 mg administered every 4 weeksduring the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than
`
`P Eligibility
`
`AgesEligible for Study:
`Genders Eligible for Study:
`Accepts Healthy Volunteers:
`Criteria
`
`Inclusion Criteria:
`
`50 Years and older
`Both
`No
`
`e Signed informed consent.
`¢ Men and women >/=S0yearsof age.
`e Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveallesions that affect the fovea as evidenced by FAin the study eye.
`¢ ETDRSbest-corrected visual acuity of: 20/40 to 20/320(letter score of 73 to 25) in the study eye at 4 meters.
`e Willing, committed, and able to return for ALLclinic visits and complete all study-related procedures.
`Able to read,(or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and
`willing to sign the informed consent form.
`Exclusion Criteria:
`
`e Anyprior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
`e Any prior or concomitant therapy with another investigational agent to treat neovascular AMDinthe study eye.
`e Anyprior treatment with anti-VEGF agentsin the study eye.
`¢ Total lesion size >12 disc areas (30.5 mm&#xfffd;, including blood, scars and neovascularization) as assessed by FA in the study eye.
`¢ Subretinal hemorrhagesthat is either 50% or more of the total lesion area,or if the blood is under the fovea andis 1 or more disc areas in size in the study eye (if the blood is
`underthe fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
`¢ Scar orfibrosis making up >50% ofthe total lesion in the study eye.
`¢ Scar,fibrosis, or atrophy involving the center of the fovea in the study eye.
`e Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
`e History of any vitreous hemorrhage within 4 weeksprior to Visit 1 in the study eye.
`e Presence of other causes of CNV inthe study eye.
`¢ Prior vitrectomy in the study eye.
`e History of retinal detachmentor treatment or surgery for retinal detachmentin the study eye.
`e Any history of macular hole of stage 2 and abovein the study eye.
`e Anyintraocular or periocular surgery within 3 months of Day | on the study eye, except lid surgery, which may not have taken place within 1 month of Day1, as longasit is
`unlikely to interfere with the injection.
`¢ History or clinical evidence of diabetic retinopathy, diabetic macular edemaoranyretinal vascular disease other than AMDineithereye.
`
`P Contacts and Locations
`
`Please refer to this study by its ClinicalTrials.gov identifier: NCT00637377
`
`Contacts
`
`Contact: Bayer Clinical Trials Contact
`
`clinical-trials-contact@bayerhealthcare.com
`
`“F| Show 212 Study Locations
`
`Sponsors and Collaborators
`Bayer
`
`Investigators
`Study Director: Bayer Study Director Bayer
`
`P More Information
`
`Additional Information:
`
`Click here and search for drug information provided by the FDA Ei
`
`
`
`Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product =a)
`
`Click here to find results for studies related to marketed products =m
`
`No publications provided
`
`Bayer Schering Pharma AG ( Therapeutic Area Head )
`Responsible Party:
`91689, EurdaCT No.: 2007-000583-25
`Study ID Numbers:
`March 12, 2008
`Study First Received:
`July 3, 2009
`Last Updated:
`
`ClinicalTrials.gov Identifier: NCT00637377 History of Changes
`Health Authority:
`Switzerland: Ethikkommission
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 6 of 11
`Page 6 of 11
`
`

`

`Keywords provided by Bayer:
`Eye diseases
`Vision Impairment and Blindness
`Eyesand Vision
`
`Study placedin the following topic categories:
`Eye Diseases
`Mitogens
`Retinal Degeneration
`Macular Degeneration
`
`Additional relevant MeSH terms:
`Growth Substances
`Eye Diseases
`Physiological Effects of Drugs
`Retinal Degeneration
`
`ClinicalTrials.gov processed this record on August 12, 2009
`
`Backto top of Main Content
`
`Seniors
`Neovascular Age-Related Macular Degeneration (AMD)
`Retinal Disease
`
`Blindness
`Endothelial Growth Factors
`Retinal Diseases
`Vision, Low
`
`Macular Degeneration
`Endothelial Growth Factors
`Pharmacologic Actions
`Retinal Diseases
`
`Contact Help Desk
`Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
`US. NationalInstitutes of Health, U.S. Department of Health & Human Services,
`USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act
`os
`oteg
`
`oM¢
`
`Linksto all studies - primarily for crawlers
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 7 of 11
`Page 7 of 11
`
`

`

`
`
` ##   
`

 



 
` #!
`https://web.archive.org/web/20090911163626/https://clinicaltrials.gov/ct2/show/NCT005097
`#
`95
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 8 of 11
`Page 8 of 11
`
`

`

`INTERNET ARCHIVE
`Wayogedmaenine
`
`
`
`https: //clinicaltrials.gov/ct2 /show/NCT00509795
`
`
`
`
`21 captures
`1 Dec 2008 - 23 Sep 2020
`
`
`Clinica[TriaIs. gov
`Home
`Search
`Study Topics Glossary
`
`arch
`
`A service of the U.S. National Institutes of Health
`I Searc'
`
`
`Full Text View
`
`Tabular View
`
`No Study Results Posted
`
`Related Studies
`
`Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular
`Degeneration(AMD)(VIEW 1)
`
`This studyis currently recruiting participants.
`Verified by Regeneron Pharmaceuticals, April 2009
`
`First Received: July 31, 2007 Last Updated: April 28, 2009 History of Changes
`
`ClinicalTrials.gov Identifier:|NCT00509795
`
`SponsorsandCollaborators: ao Pharmaceuticals
`
`
`
`Purpose
`This study is a phaseIII, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eyein patients with neovascular age-related macular degeneration. Approximately
`1200 patients will be randomized in the US and Canada.
`
`
`
`Drug: VEGF Trap-Eye
`Drug: Ranibizumab
`
`PhaseIll
`
`Macular Degeneration
`
`Interventional
`Study Type:
`Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
`Official Title:|A Randomized, Double Masked, Active Controlled PhaseII| Study of the Efficacy, Safety, and Tolerability of Repeated DosesofIntravitreal VEGF Trap in Subjects With
`Neovascular Age-Related Macular Degeneration
`
`Resourcelinks provided by NLM:
`
`Genetics Home Referencerelated topics: X-linked juvenile retinoschisis
`
`MedlinePlus related topics: Macular Degeneration
`
`Drug Information available for: Ranibizumab Aflibercept
`U.S. FDA Resources
`
`Further study details as provided by Regeneron Pharmaceuticals:
`
`Primary Outcome Measures:
`« The proportion of subjects who maintain vision at Week 52, where a subjectis classified as maintaining vision if the subject has lost fewer than 15 letters on the ETDRS
`chart comparedto baseline (i.e. prevention of moderate vision loss) [ Time Frame: Week 52 ] [ Designated as safety issue: Yes ]
`
`Secondary Outcome Measures:
`« Mean changefrom baseline in BCVA as measured by ETDRSletter score at Week 52 [ Time Frame: Week 52 ] [ Designated assafety issue: Yes]
`« The proportion of subjects who gain at least 15 letters of vision at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
`« Mean changefrom baselinein total NEI VFQ-25 score at Week 52 [ Time Frame: Week52 ] [ Designated as safety issue: No ]
`« Mean changefrom baseline in CNV area at Week 52 [ Time Frame: Week 52] [ Designated as safety issue: Yes ]
`
`1200
`Estimated Enrollment:
`August 2007
`Study Start Date:
`December2011
`Estimated Study Completion Date:
`Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
`
`jarms|AssignedInterventions
`1:
`Drug: VEGF Trap-Eye
`Experimental
`0.5 mg VEGF Trap-Eye administered every 4 weeks duringthefirst year. Thereafter a dose may be administered as frequently as every 4 weeks, but
`no less frequently than every 12 weeks.
`
`than every 12 weeks.
`
`2:
`Experimental
`
`Drug: VEGF Trap-Eye
`2.0 mg VEGF Trap-Eye administered every 4 weeks during thefirst year. Thereafter a dose may be administered as frequently as every 4 weeks,but
`no less frequently than every 12 weeks.
`
`3:
`Experimental
`
`Drug: VEGF Trap-Eye
`2.0 mg VEGF Trap-Eye administered every 8 weeks(including one additional 2.0 mg doseat week4) during thefirst year. Thereafter a dose may be
`administered as frequently as every 4 weeks,but no less frequently than every 12 weeks.
`
`4: Active
`Comparator
`
`Drug: Ranibizumab
`0.5 mg administered every 4 weeks during the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 9 of 11
`Page 9 of 11
`
`

`

`Eligibility
`
`AgesEligible for Study:
`GendersEligible for Study:
`Accepts Healthy Volunteers:
`Criteria
`
`50 Years and older
`Both
`No
`
`KeyInclusion Criteria:
`1.
`Signed Informed Consent.
`2.
`Men and women= 50 yearsof age.
`3.
`Active primary or recurrent subfoveal CNV lesions secondary to AMD,including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.
`4.
`ETDRSbest-corrected visual acuity of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye.
`5.
`Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
`6.
`Able to read,(or, if unable to read dueto visual impairment, be read to verbatim by the person administering the informed consentor a family member. See Appendix J.4)
`understand andwilling to sign the informed consent form.
`
`arwon
`oOONOD
`
`Key Exclusion Criteria:
`1.
`Anyprior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplementsor vitamins.
`. Any prior or concomitant therapy with anotherinvestigational agent to treat neovascular AMD in the study eye, except dietary supplementsorvitamins.
`. Any prior treatment with anti-VEGF agentsin the study eye.
`. Total lesion size > 12 disc areas (30.5 mm2,including blood, scars and neovascularization) as assessed by FA in the study eye.
`. Subretinal hemorrhagethatis either 50% or moreof the total lesion area,orif the blood is under the fovea and is 1 or more disc areasin sizein the study eye. (If the blood
`is underthe fovea, then the fovea must be surrounded 270 degreesbyvisible CNV.)
`. Scar or fibrosis, making up > 50% of totallesion in the study eye.
`. Scar, fibrosis, or atrophy involving the center of the fovea.
`. Presenceofretinal pigment epithelial tears or rips involving the macula in the study eye.
`. History of any vitreous hemorrhage within 4 weeksprior to Visit 1 in the study eye.
`. Presence of other causes of CNVin the study eye.
`. History or clinical evidence of diabetic retinopathy, diabetic macular edemaor any other vascular disease affecting the retina,other than AMD, in either eye.
`12.
`Prior vitrectomyin the study eye.
`13.
`History of retinal detachmentor treatment or surgery forretinal detachmentin the study eye.
`14.
`Anyhistory of macular hole of stage 2 and abovein the study eye.
`15.
`Anyintraocular or periocular surgery within 3 months of Day 1 on the study eye, exceptlid surgery, which may not have taken place within 1 month of day1, as long asits
`unlikely to interfere with the injection.
`
`Contacts and Locations
`
`Pleasereferto this study by its ClinicalTrials.gov identifier: NCT00509795
`
`Contacts
`Contact: Regeneron
`
`866-549-8439 VIEWistudy@rtp.ppdi.com
`
`=| Show 191 Study Locations
`Sponsorsand Collaborators
`Regeneron Pharmaceuticals
`Bayer
`
`Investigators
`Study Director: Avner Ingerman, MD Regeneron Pharmaceuticals
`
`MoreInformation
`
`No publications provided
`
`Regeneron Pharmaceuticals ( Dr. Avner Ingerman )
`Responsible Party:
`VGFT-OD-0605
`Study ID Numbers:
`July 31, 2007
`Study First Received:
`April 28, 2009
`Last Updated:
`History of Changes
`ClinicalTrials.gov Identifier: NCT00509795
`Health Authority:
`United States: Food and Drug Administration; Canada: Health Canada
`
`Study placedin the following topic categories:
`Eye Diseases
`Mitogens
`Retinal Degeneration
`Additional relevant MeSH terms:
`Growth Substances
`Eye Diseases
`Physiological Effects of Drugs
`Retinal Degeneration
`
`Macular Degeneration
`Endothelial Growth Factors
`Retinal Diseases
`
`Macular Degeneration
`Endothelial Growth Factors
`Pharmacologic Actions
`Retinal Diseases
`
`ClinicalTrials.gov processed this record on September 11, 2009
`
`
`Contact Help Desk
`Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
`U.S. NationalInstitutes of Health, U.S. Department of Health & Human Services,
`USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act
`
`\p_US. NationalInstitutes of Health |pUS: National Library of Medicine |pUS: Departmentof Health & Human Services
`
`Apotex Exhibit 1022
`Apotex Exhibit 1022
`Page 10 of 11
`Page 10 of 11
`
`

`

`(cid:45)(cid:56)(cid:53)(cid:36)(cid:55)
`
`(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:18) )'')(0 &-#)!(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`FLORIDA
`
` $-2(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3) ).(-2 (cid:3)(cid:3)(cid:3))!(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`Broward
`
`(cid:12)(cid:3)
`(cid:12)(cid:3)(cid:3)(cid:3)
`(cid:12)(cid:3)
`
`(cid:50)(cid:81)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:15)(cid:3)(cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:3)(cid:80)(cid:72)(cid:15)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)(cid:15)(cid:3)
`Mikhail Clarke
`01/27/2021
`(cid:39)(cid:68)(cid:87)(cid:72)
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:49)(cid:68)(cid:80)(cid:72)
`(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:74)(cid:82)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:86)(cid:87)(cid:85)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87) (cid:90)(cid:68)(cid:86) (cid:86)(cid:88)(cid:69)(cid:86)(cid:70)(cid:85)(cid:76)(cid:69)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:90)(cid:82)(cid:85)(cid:81)(cid:3)(cid:11)(cid:82)(cid:85)(cid:3)(cid:68)(cid:73)(cid:73)(cid:76)(cid:85)(cid:80)(cid:72)(cid:71)(cid:12) (cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72) (cid:80)(cid:72)(cid:3)(cid:69)(cid:92)(cid:29)
`
`(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:17)
`Duncan Hall
`(cid:49)(cid:68)(cid:80)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:73)(cid:73)(cid:76)(cid:68)(cid:81)(cid:87)(cid:11)(cid:86)(cid:12)
`(cid:137) (cid:51) +,)(&&2 %()0( -) ' (cid:16)(cid:16)(cid:3)(cid:50)(cid:53)(cid:3)(cid:16)(cid:16)
`(cid:137) (cid:51)+)/  -) ' )( -# ,$, )! (cid:87)(cid:75)(cid:72)(cid:3)(cid:82)(cid:68)(cid:87)(cid:75)(cid:3)(cid:82)(cid:73)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)(cid:16)(cid:16)(cid:3)(cid:50)(cid:53)(cid:3)(cid:16)(cid:16)
` (cid:3)(cid:82)(cid:73)(cid:3)(cid:38)(cid:85)(cid:72)(cid:71)(cid:76)(cid:69)(cid:79)(cid:72)(cid:3)(cid:58)(cid:76)(cid:87)(cid:81)(cid:72)(cid:86)(cid:86)
`(cid:137) (cid:51)(cid:85)(cid:82)(cid:89)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:69)(cid:68)(cid:86)(cid:76)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:72)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:70)(cid:72)(cid:29)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`driver_license
`(cid:137)
`(cid:55)(cid:92)(cid:83)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:44)(cid:39)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:72)(cid:71)
`
`Notarized online using audio-video communication
`
` '2 #( ( )!!$$& , &
`
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:51)(cid:88)(cid:69)(cid:79)(cid:76)(cid:70)(cid:3)$"(-.+  (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`
`(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)
`
`
`(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:49)(cid:68)(cid:80)(cid:72)(cid:29)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`Mikhail Clarke
`)-+(cid:92) (cid:38)(cid:82)(cid:80)(cid:80)(cid:76)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81) .' +(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)
`HH7610
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3) )''$,,$)( 1*$+ ,(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`06/08/2024
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:79)(cid:76)(cid:81)(cid:72)(cid:3)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:82)(cid:16)(cid:89)(cid:76)(cid:71)(cid:72)(cid:82)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:88)(cid:81)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
`
`(cid:39)(cid:40)(cid:54)(cid:38)(cid:53)(cid:44)(cid:51)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)(cid:50)(cid:41)(cid:3)(cid:36)(cid:55)(cid:55)(cid:36)(cid:38)(cid:43)(cid:40)(cid:39)(cid:3)(cid:39)(cid:50)(cid:38)(cid:56)(cid:48)(cid:40)(cid:49)(cid:55)
`
`(cid:55)(cid:76)(cid:87)(cid:79)(cid:72)(cid:3)(cid:82)(cid:85)(cid:3)(cid:55)(cid:92)(cid:83)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`Affidavit of Authenticity
`
`(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:39)(cid:68)(cid:87)(cid:72)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`01/27/2021
`
`(cid:49)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:51)(cid:68)(cid:74)(cid:72)(cid:86)(cid:3)(cid:11)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:81)(cid:82)(cid:87)(cid:68)(cid:85)(cid:76)(cid:68)(cid:79)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:87)(cid:72)(cid:12)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`11
`
`Apotex Exhibit 1022
`Page 11 of 11
`
`